Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting

Abstract

BACKGROUND The 2015 Coffey-Holden Prostate Cancer Academy Meeting, themed: “Multidisciplinary Intervention of Early, Lethal Metastatic Prostate Cancer,” was held in La Jolla, California from June 25 to 28, 2015. METHODS The Prostate Cancer Foundation (PCF) sponsors an annual, invitation-only, action-tank-structured meeting on a critical topic concerning lethal prostate cancer. The 2015 meeting was attended by 71 basic, translational, and clinical investigators who discussed the current state of the field, major unmet needs, and ideas for addressing earlier diagnosis and treatment of men with lethal prostate cancer for the purpose of extending lives and making progress toward a cure. RESULTS The questions addressed at the meeting included: cellular and molecular mechanisms of tumorigenesis, evaluating, and targeting the microenvironment in the primary tumor, advancing biomarkers for clinical integration, new molecular imaging technologies, clinical trials, and clinical trial design in localized high-risk and oligometastatic settings, targeting the primary tumor in advanced disease, and instituting multi-modal care of high risk and oligometastatic patients. DISCUSSION This article highlights the current status, greatest unmet needs, and anticipated field changes that were discussed at the meeting toward the goal of optimizing earlier interventions to potentiate cures in high-risk and oligometastatic prostate cancer patients.

PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges

“…Multiple clinical trials are currently underway to assess the best approach for the treatment of oligometastatic disease in PCa. 71 …”

Tumor cell heterogeneity and resistance; report from the 2018 Coffey‐Holden Prostate Cancer Academy Meeting

“…For six consecutive years, PCF has convened the Coffey‐Holden Prostate Cancer Academy (CHPCA) Meeting, an annual “think tank” conference, which gathers ∼75 investigators to discuss the most critical topics necessary for making a near‐term impact on the understanding and treatment of lethal prostate cancer . This meeting is uniquely designed to promote deep and ample discussion and brainstorming of necessary next steps by structuring sessions into short talks with lengthy discussion times.…”

Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey‐Holden Prostate Cancer Academy Meeting

“…The Coffey‐Holden Prostate Cancer Academy (CHPCA) Meeting is an annual conference convened by PCF that gathers ∼75 investigators to discuss the most critical avenues of research that necessitate study in order to accelerate improved treatments for men with advanced prostate cancer . The CHPCA Meeting is uniquely structured into short talks followed by long discussions for the purpose of generating a “think tank” atmosphere that stimulates brainstorming and the development of strategic new ideas, projects, and collaborations in most needed areas of research.…”

“…The Coffey-Holden Prostate Cancer Academy (CHPCA) Meeting is an annual conference convened by PCF that gathers ∼75 investigators to discuss the most critical avenues of research that necessitate study in order to accelerate improved treatments for men with advanced prostate cancer. [1][2][3][4] The CHPCA Meeting is uniquely structured into short talks followed by long discussions for the purpose of generating a These included: biology and treatment approaches for aggressive variant castrate resistant prostate cancer (CRPC), epigenetic regulation of CRPC, the role of DNA repair gene mutations in driving prostate and other cancers, strategic approaches to delivering germline genetics into actionable clinical practice, development of targeted radionuclides for imaging and therapy, advances in molecular imaging, and therapeutic strategies for successful use of immunotherapy in advanced prostate cancer. In addition to prostate cancer, experts from several other major fields unrelated to prostate cancer research attended and contributed fresh research insights and lessons from breast cancer, ovarian cancer, and astronomy/high-dimension informatics that may be applied to improve studies in prostate cancer.…”